Full-Time

Associate Director

LNP Process Development

Posted on 11/12/2024

Editas Medicine

Editas Medicine

201-500 employees

Develops gene editing treatments using CRISPR

Biotechnology

Senior, Expert

Cambridge, MA, USA

Category
Lab & Research
Life Sciences
Medical Research
Required Skills
Data Analysis
Requirements
  • Degree in Chemical Engineering, Biomedical Engineering, Chemistry, Pharmaceutical Sciences, or related discipline with 8+ (Ph.D.), 10+ (M.S.), 12+ (B.S.) years of relevant experience in drug development
  • Strong technical expertise and hands-on experience in state-of-the-art LNP process development, optimization, and scale-up as demonstrated through publication records, patent filings or meaningful work in a drug development setting are required
  • In-depth expertise in LNP manufacturing technique [e.g. T-mixing and tangential flow filtration (TFF)] is a must
  • Ability to apply Quality-by-Design (QbD) principles to process development strategy planning and execution is required
  • Advanced skills in experimental design (e.g. DOE) and data analyses using relevant statistical software packages (e.g. JMP) for process development, process characterization or formulation screening are highly preferred
  • Working knowledge of LNP, mRNA, and pertinent raw material (e.g. lipids) characterization methods and specifications is highly desirable
  • Exceptional leadership and interpersonal skills as well as excellent presentation and scientific/technical writing skills is a must
  • Strong organizational skills, and ability to multi-task, problem-solve, and adjust priorities to meet goals in a fast-paced environment.
  • Experience in leading a team of direct reports and providing guidance and mentorship to junior engineers or scientists.
  • Experience in leading cross-functional collaborations with other internal departments as well as external CDMOs.
  • Understanding of LNP related industry guidance’s (FDA, PDA, ICH and BPOG), knowledge of FDA, EMA and ICH regulations, and understanding of product development life cycle.
Responsibilities
  • Lead and grow a team of engineers to define and drive the execution of Process Development strategy for LNP as drug delivery vehicle towards IND and clinical manufacturing
  • Lead the design and build out of an internal LNP PD lab including lab space planning, new equipment procurement, installation and training
  • Responsible for production of representative LNP materials for analytical development and formulation development studies
  • Lead technology transfer of LNP manufacturing process to external manufacturing facilities for pre-clinical and clinical manufacturing, in collaboration with other Tech Dev teams as well as the Manufacturing and Quality teams at Editas
  • Provide technical oversight of external LNP process development activity and pre-clinical and clinical manufacturing (e.g. review of SoW, study report, batch records, support of troubleshooting/deviation investigation, and onsite PIP).
  • Act as the lead Subject Matter Expert for LNP process science to direct the establishment and continuous improvement of LNP platform manufacturing processes through well-coordinated external and internal development efforts
  • Perform a wide range of managerial duties pertaining to employees including hiring, on-the-job training, career development, appraising performance, and promotions. Identify opportunities and provide the means for employees to pursue career growth.
  • Lead cross-functional projects/working teams, champion new ideas/business process improvements to advance company’s LNP pipeline and technology platforms
  • Support CMC strategy development, implementation, and refinement for pertinent programs through strong collaboration with key stakeholders and external partners
  • Author and review of regulatory submissions, technical reports, SOPs and work instructions
  • Maintain abreast latest industry trends for LNP process and product knowledge, work cross-functionally (e.g. with Research, Business Development and Legal) to evaluate novel manufacturing technologies and new business partners
  • Lead the team to be responsible for RNP process development activities including Process Characterization to drive PPQ readiness, technical support of PPQ and clinical manufacturing and regulatory filing, as well as Process development and Tech transfer support for early-stage programs

Editas Medicine focuses on gene editing using CRISPR technology, which allows for precise modifications to DNA in cells. This technique has the potential to correct genetic defects that lead to various diseases. The company is engaged in the entire process of drug development, from discovering new treatments to manufacturing and selling them. Editas Medicine aims to create effective and lasting therapies that can enhance the quality of life for patients suffering from serious health conditions. Unlike many competitors, Editas has a diverse pipeline of experimental medicines and actively shares clinical data to keep stakeholders informed. The ultimate goal is to provide transformative treatments for patients worldwide.

Company Stage

IPO

Total Funding

$321M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

2%

1 year growth

22%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Genevant Sciences could enhance targeted delivery systems for gene therapies.
  • $50 million financing with DRI Healthcare Trust supports pipeline advancement and in-vivo programs.
  • Promising EDIT-101 trial results show potential to treat genetic blindness effectively.

What critics are saying

  • 65% workforce reduction may cause operational challenges and development delays.
  • Pivot to in-vivo gene editing increases competition and pressure to demonstrate efficacy.
  • Unsuccessful sickle cell partnership search indicates potential strategic alliance difficulties.

What makes Editas Medicine unique

  • Editas Medicine uses CRISPR technology for precise gene editing in therapeutics.
  • The company focuses on in-vivo gene editing, targeting stem cells and the liver.
  • Editas has a strong intellectual property portfolio in genome editing technologies.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE